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Abstract
Background Diabetic retinopathy is severe damage to the
retina caused by complications of diabetes, and is the prevail-
ing cause of blindness. Accumulating evidence from both
animal models and humans suggests that the inflammatory
process plays a key role in the development of diabetic reti-
nopathy and is facilitated by innate immune response. The aim
of this study was to examine whether the TLR4 signaling
pathway was involved in the streptozotocin-induced diabetic
rat retina.
Methods Diabetes was induced by a single intraperitoneal
injection of streptozotocin, and rat diabetic retinopathy was
examined at 4 weeks of diabetes duration. Then the accumu-
lated leukocytes were counted in vivo by acridine orange
leukocyte fluorography, and the retinal vascular permeability
was measured by the Evans blue assay. The expressions of
TLR4 and its downstream signaling molecules were measured
byRT-PCR orWestern blot respectively. To evaluate the effect
of blocking TLR4 on diabetic retinopathy, TAK-242, a selec-
tive TLR4 antagonist, was administered by intraperitoneal
injection.
Results Our results showed that the retina of diabetic rats
demonstrated accumulated leukocytes and retinal vascular
permeability. The mRNA and protein expressions of TLR4
were upregulated in streptozotocin-treated diabetic rat retina.
Furthermore, the protein levels of TLR4 downstream signal-
ing molecules were significantly increased in streptozotocin-
treated animals. In addition, the protein levels of tumor necro-
sis factor (TNF)-α, interleukin (IL)-1β, and interferon
(IFN)-β, three downstream proinflammatory cytokines of
TLR4 signal transduction pathway, were also markedly in-
creased in diabetic rats. Administration of TAK-242 attenuat-
ed leukocytes accumulated and retinal vascular permeability,
and decreased TLR4 downstream signaling molecules and
proinflammatory cytokines in streptozotocin-induced
animals.
Conclusions Together, these data have demonstrated that
TLR4 has a critical role in streptozotocin-induced diabetic
retinopathy at the level of inflammatory cytokine induction,
in both the MyD88-dependent and MyD88-independent path-
ways. TLR4 may become a new potential pharmacological
target for treating diabetic retinopathy.
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Introduction
Diabetic retinopathy (DR) is a highly specific vascular com-
plication of both type 1 and type 2 diabetes, which is an
mainly ocular manifestation of diabetes. The severity of reti-
nopathy is closely related to the times for diabetes_ENREF_1.
After about 20 years duration of diabetes, almost all type 1
diabetes patients and more than 60 % type 2 diabetes patients
have some degree of retinopathy [1]. DR is mainly related
with new cases of blindness among adults aged from 20 to
74 years [2]. In clinic, DR is characterized by early breakdown
of the blood–retinal barrier (BRB), which gives rise to vision
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loss via macular edema or vitreoretinal neovascularization [3].
Recent researches showed many new intriguing pathways
involved in pathogenesis of DR, e.g., protein kinase
(PK)Cb/HuR/ vascular endothelial growth factor (VEGF)
pathway [4]. However, the exact mechanism underlying DR
still remains elusive. Therefore, the use of existing agents for
treating DR often has limited efficacy and are associated with
unwanted side-effects.
Accumulating evidence from both animal models and
humans suggests that the inflammatory process plays a key
role in the development of DR, and is facilitated by innate
immune response [5–8]. Retinal vasculature in diabetes is
accompanied by inflammatory cell adhesion [9], which causes
vascular hyperpermeability [10] and pathologic retinal neo-
vascularization [11]. Recently, it has been reported that the
innate immune response is mediated by a number of receptors
known as Toll-like receptors (TLRs), which are stimulated by
different microbial stimuli [12]. On binding to the relevant
ligands, these receptors could activate different signal trans-
duction pathways that produce the induction of proinflamma-
tory cytokines and up-regulation of costimulatory molecules
[13]. TLRs also play a important role in connecting between
the innate and adaptive immune responses [14]. TLR4, in
particular, is gradually being considered to be the important
modulator of neuronal survival in the brain during non-
pathogen (sterile) injuries [15, 16]. Studies conducted in ani-
mal models of diabetes have showed that TLR4 pathways
were implicated in mechanisms linked with both diabetes
induction and prevention [17]. An up-regulation of TLR4
level has been accompanied by the increased inflammatory
response in diabetic patients [18, 19]. Genetic deficiency of
TLR4 significantly abrogates the pro-inflammatory state of
diabetes [20]. Furthermore, TLR4 expression and localization
in the retina has also been extensively studied and reported
[21–23]. Therefore, it may be reasonable to postulate that
TLR4 is involved in inflammation in diabetes and plays a
putative role in the retinopathy of streptozotocin-induced
diabetes.
In the present study, we employed streptozotocin-
induced diabetic rats and normal control rats to identify
key roles for TLR4 signaling in the retinopathy of
streptozotocin-induced diabetes. To evaluate the effect of
blocking TLR4 on diabetic retinopathy, TAK-242, a selec-
tive TLR4 antagonist, was also administered by intraperito-
neal injection. The streptozotocin-induced DR animal mod-
el was confirmed by measuring the retinal leukocyte accu-
mulation and retinal vascular permeability. Then, the ex-
pressions of TLR4 and its signal transduction factors were
measured by RT-PCR or Western blot respectively. In addi-
tion, the protein levels of tumor necrosis factor (TNF)-α,
interleukin (IL)-1β, and interferon (IFN)-β, three down-
stream proinflammatory cytokines of TLR4 signal trans-
duction pathway, were also measured in diabetic rats.
Methods
Animals
Male Brown Norway rats (8–10 weeks of age, from Vital
River Laboratories of Beijing) weighing approximately 200
to 250 g (n=96) were each used in accordance with the ARVO
Statement for the Use of Animals in Vision and Ophthalmic
Research. Room temperature was maintained between 18 and
25 °C, average daily humidity between 50 and 70 %. All rats
were given ad libitum access to water and food until they were
used for the experiments.
Groups and treatment
Each rat was given a single intraperitoneal injection of
streptozotocin (60 mg/kg in 0.1 mol/l of citrate buffer,
pH 4.2–4.5) after an overnight fasting, finishing in 30 min
[24]. Blood glucose levels were measured in tail veins 5 days
after streptozotocin injection, and the diabetic condition was
established with a glucose level of ≥250 mg/dl on 3 consecu-
tive days. TAK-242 (InvivoGen, San Diego, CA, USA) was
formulated with 1 % dimethyl sulfoxide and double-distilled
water to a final concentration of 1 mg/ml, and it was intraper-
itoneally injected at a dose of 3 mg/kg once daily for 7
successive days beginning 3 weeks after streptozotocin injec-
tion. This dose was chosen on the basis of previous in-vivo
studies [25, 26]. Animals injected with an equal volume of
1 % dimethyl sulphoxide were used as vehicle-diabetic group.
Control rats received injections of citrate buffer alone. The
physiological variables of each group were measured at
4 weeks after streptozotocin injection.
Evaluation of leukocyte accumulation in rat retina
At 4 weeks after the induction of diabetes, leukocyte accumu-
lation in retinal microcirculation was evaluated with acridine
orange (AO) digital fluorography, which has been described
previously [24, 27]. Eight different rats were used in each
group. This technique uses a scanning laser ophthalmoscope
(Heidelberg Engineering), which makes high-resolution im-
ages of fundus stained by AO (Sigma Chemical). Before AO
digital fluorography, rats were anesthetized with xylazine
hydrochloride and ketamine hydrochloride (10 mg/kg) and
their pupils were dilated with 0.5 % tropicamide and 2.5 %
phenylephrine hydrochloride. Body temperature was main-
tained between 37 and 39 °C throughout the experiment.
AO (0.1 % solution in saline) was injected continuously via
the jugular vein at a rate of 1 ml/min. Thirty minutes after the
injection, the fundus was detected with the scanning laser
ophthalmoscope for evaluation of leukocyte accumulation in
the retinal microcirculation. The video images in real time to
640 horizontal and 480 vertical pixels with an intensity
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resolution of 256 steps were captured individually with a
frame-grabber for later processing. For evaluating retinal
leukostasis, an observation area around the optic disc measur-
ing 5 disc diameters in diameter was observed by drawing a
polygon surrounded by the adjacent major retinal vessels. The
area was measured in pixels, and the density of trapped
leukocytes was calculated by dividing the number of trapped
leukocytes, which were recognized as fluorescent dots, by the
area of the observation region. The densities of leukocytes
were calculated generally in eight peripapillary observation
areas, and an average density was acquired by averaging the
eight density values [10].
Measurement of blood-retinal barrier breakdown
Rats after 4-weeks-duration diabetes were anesthetized, and
Evans blue dye (45 mg/kg; Sigma Chemical) was injected
through the jugular vein as described previously [24, 28].
After 120 min, the chest cavity was opened and rats were
perfused for 2 min at a physiological pressure through the left
ventricle with 0.05 M, pH 3.5, citrate-buffered paraformal-
dehyde (1 % wt/vol; Sigma). The perfusion solution was
warmed to 37 °C to prevent vasoconstriction. Both eyes
were enucleated and bisected at the equator immediately
after perfusion. Then retinas were carefully dissected and
thoroughly dried in a Speed-Vac for 5 h. The dry weight was
used to normalize the quantitation of Evans blue leakage.
Evans blue was extracted by incubating each retina in
120 μl formamide (Sigma) for 18 h at 70 °C. The superna-
tant was filtered through Ultrafree-MC tubes (Millipore) at
3,000 rpm for 2 h, and filtrates (60 μl) were used for
triplicate spectrophotometric measurements. Each measure-
ment occurred over a 5-s interval, and all measurements
were preceded by evaluation of known standards. The
background-subtracted absorbance was acquired by detect-
ing each sample at 620 and 740 nm. The dye level in the
extracts was calculated from a standard curve of Evans blue
in formamide. Blood-retinal barrier breakdown was calcu-
lated with the following equation, and results were
expressed in μl plasma×g retina dry wt−1 × h−1.
Evans blue μgð Þ=Retina dry weight gð Þ
Time averaged Evans blue concentration μgð Þ=Plasma μlð Þ  Circulation time hð Þ
Western blot analysis
Crude retinal extracts from healthy and 4-week diabetic
rats (n = 8 for each experimental group) were
homogenated and processed as previously described by
Guo et al. [29]. Immunoblot analyses were performed
using rabbit polyclonal antibodies for TLR4 and β-actin
(1:2000, Santa Cruz Biotechnology), MyD88, interleukin-
1 receptor-associated kinase (IRAK 1), tumor necrosis
factor receptor-associated factor (TRAF 6), TRIF-related
adaptor molecule (TRAM 1), nuclear factor kappa B
(NF-κB) p-p65, NF-κB p65 (1:1000, Santa Cruz
Biotechnology), and Toll /IL-1 receptor-domain-
containing adaptor-inducing interferon-γ (TRIF) (1:1000,
Cell Signal Technology). A secondary antibody conjugat-
ed with horseradish peroxidase (HRP, 1:5000, Bio-Rad)
was used. Immunoblots were visualized on X-ray film by
chemiluminescence reaction (Pierce), and image analysis
was performed on optical densitycalibrated images by
AlphaEase Stand Alone software (Alpha Innotech).
Protein levels were expressed as the ratio of the values
of the detected protein band to the β-actin band, except
that NF-κB p-p65 level was relative to the p 65.
Table 1 Sequences of primers used for real-time RT-PCR
Name Oligo Primer sequence Predicted size (bp) Genebank accession
TLR4 Forward primer Reverse primer 5′- TGCTCAGACATGGCAGTTTC -3′,
5′- TCAAGGCTTTTCCATCCAAC -3′;
206 HM245342
β-actin Forward primer Reverse primer 5′-ACGTTGACATCCGTAAAGAC-3′
5′-GGACTCATCGTACTCCTGCT-3′
239 BC063166
Table 2 Physiological variables for each study group
Group WBC (103/ml) Body weight (g) Blood glucose (mg/dl)
Control 6.67±1.07 278.6±22.8 127.4±12.3
DR 6.23±1.34 247.2±27.7* 406.1±24.9**
DR+vehicle 7.04±1.56 242.4±26.1* 417.6±25.7**
TAK 242 6.14±1.21 253.8±27.1* 386.4±19.4**
Data shows physiological variables of four groups 4 weeks after intravit-
real injection of streptozocin. Data are expressed as mean±SD (n=8). *
P<0.05; **P<0.01 indicates a significant difference compared with the
control group. WBC, peripheral leukocyte count
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Real-time quantitative PCR
Retinas from healthy and 4-week diabetic rat retinas (n = 8 for
each experimental group) were isolated, and the total RNA
was obtained using TRIzol method. The concentration of
RNA was measured by an absorbance at 260 nm. First-
strand cDNA was done by using Superscript-II (Invitrogen,
Burlington, ON, Canada) system and the resulting products
were stored at −20 °C. Then, real-time quantitative PCR
analyses for TLR4 and β-actin were performed in 96-well
plates using the ABI PRISM 7700 Sequence Detection
System instrument and software (PE Applied Biosystems).
PCR was performed by using the SYBR Green PCR Master
Mix (Applied Biosystems) according to the manufacturer’s
protocol, with the following oligonucleotide primers: TLR4-
forward 5′- TGCTCAGACATGGCAGTTTC -3′and reverse
5′- TCAAGGCTTTTCCATCCAAC-3′ (206 bp); β-actin-
forward 5′- ACGTTGACATCCGTAAAGAC-3′ and reverse
5′- GGACTCATCGTACTCCTGCT-3′ (239 bp). The primers
were designed to span an exon–exon junction, and there is
also an intron between 5′ and 3′ primer at the genomic DNA.
The basic protocol for real-time PCR was an initial incubation
at 95 °C for 5 min, followed by 40 cycles of 94 °C for 30 s,
54 °C for 30 s, and 72 °C for 1 min. All samples were run in
triplicate; the relative expression values were normalized with
β-actin value. To quantify the results measured by real-time
RT-PCR, plasmids containing cDNA were used as standard.
The interest cDNAwas amplified by RT-PCR using the same
premiers as for RT-PCR. The PCR products were cloned into
pGEM-T easy vector (Invitrogen) and confirmed by sequence
information. The purified recombinant plasmid DNA was
detected by UV spectrophotometer and then proportionally
diluted (1:10) in double-distilled water as standard for numer-
ical quantification. The standard curve was prepared for each
gene, and β-actin was used as housekeeping gene in this
study.
The TLR 4 mRNA copies relative to β-actin mRNAwere
calculated as TLR 4 mRNA expression (normalized value).
The PCR products were run on 1.5 % agarose gels. Melting
curve was also analyzed after PCR amplification. Table 1
shows the primer sequences.
Enzyme-linked immunosorbent assay (ELISA)
Retinas from healthy and 4-week diabetic rats (n = 8 for each
experimental group) were isolated and homogenized followed
by centrifugation. The concentrations of IL-1β, TNF-α, and
IFN-β were measured by enzyme-linked immunosorbent as-
say (ELISA) kits (Invitrogen), and were normalized with a
protein assay kit.







Fig. 1 Evaluation of leukocyte (white arrows) accumulation by AO
fluorography. a Few leukocytes were found in the control retinas. b The
number of accumulating leukocytes was significantly increased in the
DM. cAbout the same number of leukocytes accumulated in the retina of
the vehicle-treated DM rats as were seen in the untreated DM rats. d A
significant reduction in the number of accumulated leukocytes was seen
in the retina of the TAK 242-treated DM rats. e Evaluation of leukocyte
lccumulation in rat retina. All the data are given as the mean±SD (n=8).
**P<0.01 indicates a significant difference compared with the control
group, ## P<0.01 indicates a significant difference compared with the
vehicle-treated diabetic retinas group




Fig. 2 Measurement of blood–retinal barrier breakdown. All the data are
given as the mean±SD (n=8). **P<0.01 indicates a significant differ-
ence compared with the control group, ## P<0.01 indicates a significant
difference compared with the vehicle-treated diabetic retinas group
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Statistical analysis
All the data are given as the mean±SD for parametric data.
The statistical analysis was performed using the SAS.
Parametric data were analyzed with two-tailed t-tests, whereas
non-parametric data were analyzed with Mann–Whitney U




Table 2 indicates the physiological variables of each
group. There was no significant difference among groups
in peripheral leukocyte count (WBC). The blood glucose
level was significantly higher than the control group in all
three other groups, whereas the body weight was mark-
edly decreased. No significant difference was found
among those three groups in blood glucose levels and
body weight.
Evaluation of leukocyte accumulation in rat retina
Figure 1 shows that the leukocyte accumulation in the retinal
microcirculation of diabetic rats (6.2±0.69×10−5 cells/pixel2)
and diabetic+vehicle rats (6.4±0.73×10−5 cells/pixel2) was
significantly increased compared with the control group (2.2±
0.32×10−5 cells/pixel2, P<0.01). After TAK-242 treatment,
leukocytes reduced to 44.3 % compared with vehicle-treated
diabetic group (P<0.01).
control    DR    DR+vechile  TAK 242
** **
##









Fig. 3 Real-time PCR analysis of
TLR4 in the retinas. a Agarose
gel electrophoresis to determine
the length of amplification gene in
RT-PCR. The length of PCR
products is 239 bp (β-actin) and
206 bp (TLR4). b RT-PCR-
melting curve. c Gene level of
TLR4 in the retinas. Data are
given as the mean±SD (n=8).
**P<0.01 indicates a significant
difference compared with the
control group, ## P<0.01
indicates a significant difference
compared with the vehicle-treated
diabetic retinas group
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Measurement of blood–retinal barrier breakdown
To determine the correlation between leukocyte accumulation
and BRB breakdown, the Evans blue assay was performed to
detect the retinal blood vessel leakage. As shown in Fig. 2, the
data of retinal Evans blue leakage in diabetic retinopathy
group (24.42±1.84 ng/mg) and diabetic+vehicle group
(26.37±2.96 ng/mg) was markedly higher than that in control
(13.23±1.70 ng/mg, P<0.01). Injection of TAK-242 de-
creased blood–retinal barrier breakdown in the diabetic retinas
by 65.5 % compared with the vehicle-treated diabetic group
(P<0.01).
TLR4 gene and protein expression in the retinas
The length of amplification gene of TLR 4 and β-actin corre-
sponds with design length (Fig. 3a) and RT-PCR-melting
curve shows no miscellaneous peak and nonspecific amplifi-
cation (Fig. 3b). As shown in Fig. 3c, compared with control
group (1.181±0.502), the TLR4 mRNA expression in the
diabetic group (2.159±0.872, P<0.01) and vehicle-treated
diabetic group (2.242±0.779, P<0.01) was significantly in-
creased after streptozotocin treatment. TAK-242 treatment
reduced TLR4 mRNA expression to 68.7 % compared with
vehicle-treated diabetic group (P<0.01). Meanwhile, the
TLR4 protein level in the diabetic group (0.316±0.071) and
vehicle-treated diabetic group (0.335±0.067) was also higher
than that in the control group (0.138±0.023, P<0.01, Fig. 4).
After TAK-242 treatment, TLR-4 protein level reduced to
63.6 % compared with vehicle-treated diabetic group
(P<0.01).
Expression of TLR4 downstream signaling molecules
Compared with the control group (0.212±0.047, 0.239±
0.044, 0.148±0.025, 0.261±0.084, 0.123±0.037, and 0.230
±0.087 respectively), the protein expressions of TLR4 down-
stream signaling molecules MyD88, IRAK, TRAF, TRAM,
TRIF, and NF-κB were significantly upregulated in the dia-
betic retinas (0.483±0.110, 0.520±0.094, 0.319±0.047,
0.504±0.125, 0.376±0.088, and 0.497±0.112, all P<0.01,)
and vehicle-treated diabetic group (0.494±0.10, 0.523±
0.0949, 0.325±0.054, 0.483±0.085, 0.341±0.12, and 0.469
±0.0881, all P<0.01, Fig. 5). TAK-242 treatment significantly
reduced these proteins levels compared with the vehicle-
treated diabetic rats (0.303±0.066, 0.291±0.068, 0.206±
0.044, 0.290±0.033, 0.181±0.060, and 0.320±0.062,
P<0.01).
Pro-inflammatory cytokines in retina homogenate supernatant
The protein levels of TNF-α, IL-1β and IFN-β in the diabetic
group (72.4±9.8 pg/mg, 54.0±8.9 pg/mg and 54.7±9.9 pg/
mg respectively) and vehicle-treated diabetic group (74.6±
12.9 pg/mg, 52.1±10.4 pg/mg and 53.1±13.3 pg/mg respec-
tively) were significantly higher than those in the control
group (40.8±7.1 pg/mg, 24.2±3.8 pg/mg and 11.5±3.1 pg/
mg, all P<0.01 Fig. 6). Meanwhile, it was significantly sup-
pressed in the TAK-242-treated group (57.2±11.9 pg/mg,
30.8±7.9 pg/mg and 20.8±6.7 pg/mg, all P<0.01).
Discussion
In the current study, we demonstrate that the expression of
TLR4 is increased in a rat model of streptozotocin-induced
diabetic retinopathy. Both TLR4 protein and mRNA expres-
sions were significantly increased after experimental diabetic
retinopathy. Furthermore, the protein levels of TLR4 down-
stream signaling molecules were significantly increased in
streptozotocin-treated animals. In addition, the retina release
of TNF-α, IL-1β, and IFN-β, three downstream proinflam-
matory cytokines of TLR4 signal transduction pathway, are
also significantly increased in streptozotocin-induced diabetic
rats. Administration of TAK-242 attenuated leukocytes accu-
mulated and retinal vascular permeability, and decreased
TLR4 downstream signaling molecules and proinflammatory
cytokines in streptozotocin-induced animals. These results
suggest that TAK-242, a specific inhibitor of TLR4 signaling,
might be effective for the alleviation of streptozotocin-
induced diabetic retinopathy animal model.














































Control  DR  DR+vehicle  TAK242
Fig. 4 Western blot analysis of TLR4 protein in the retinas. a Gel
electrophoresis images of TLR4. b Protein levels of TLR4 in the retinas.
Data are given as the mean±SD (n=8). **P<0.01 indicates a significant
difference compared with the control group, ## P<0.01 indicates a
significant difference compared with the vehicle-treated diabetic retinas
group
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Autoimmune diabetes (Type I diabetes) results from
immune-mediated beta cell destruction and is accompanied
by islet-directed antibodies, while T-cell-mediated and
cytokine-mediated cytotoxicity is thought to lead to beta cell
destruction [30]. There is still not enough available data about
the autoimmune process leading to diabetes, its complications,
and the nature of the inflammatory response [31].
Streptozotocin is a small molecule that causes depletion of
the pancreatic islet cells after systemic administration in ro-
dents. In the present study, we have shown that the blood
sugar concentration in streptozotocin-injected rats were over








































































Control  DR  DR+vehicle  TAK242
Fig. 5 Expression of the
downstream signaling molecules
in TLR4 signaling pathway. aGel
electrophoresis images of
downstream signaling molecules
in TLR4 signaling pathway. b
Protein levels of TLR4
downstream signaling molecules
in the retinas. All the data are
given as the mean±SD (n=8).
**P<0.01 indicates a significant
difference compared with the
control group, ## P<0.01
indicates a significant difference






































Fig. 6 Proinflammatory cytokines levels in retina homogenate superna-
tant. Data are given as the mean±SD (n=8). **P<0.01 indicates a
significant difference compared with the control group, ## P<0.01 indi-
cates a significant difference compared with the vehicle-treated diabetic
retinas group
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consumptions were increased (data not shown), while the
body weights were decreased significantly. DR caused by
systemic changes in metabolic and cardiovascular control is
a major complication of diabetes, and is also linked to
leukostasis, capillary occlusion, and BRB breakdown.
Adherent leukocytes lead to bleeding, elevated vascular per-
meability, and the formation of nonperfused areas [9, 32, 33].
Leukocytes accumulating in the retina could injure the tissue
directly through inflammatory responses or via the formation
of hard exudate that disrupt retinal transparency [10]. The
increase in vascular permeability leads to clinical retinal ede-
ma and, when it involves the macula, can cause loss of visual
acuity [31]. These are early clinical features of diabetic reti-
nopathy, which is the important stage for preventing the
progression of DR [33]. Here, both retinal leukocyte accumu-
lation and vascular permeability were significantly increased
in retina of streptozotocin-induced diabetic rats. Taken togeth-
er, the above results indicated the DR animal model was
successfully established.
TLRs are transmembrane pattern-recognition receptors that
play a key role in the initiation of innate immunity against
invading microbial pathogens. These single membrane-
spanning proteins bear a leucine-rich extracellular domain,
through which they recognize pathogen-associated molecular
patterns (PAMPs), leading to the transcriptional activation of
genes encoding for pro-inflammatory cytokines, chemokines,
and co-stimulatory molecules. Each TLR is now believed to
recognize a discrete collection of molecules of microbial
origin, and to signal the presence of infections. TLR4 in
particular is gradually being considered to be as a modulator
of neuronal survival in the brain during non-pathogen (sterile)
injuries [16]. TLR4 is up-regulated in many neurodegenera-
tive diseases and neuronal injuries, and has been found to
steadily increase after neurons are exposed to toxic proteins
and lipid peroxidation [16]. To date, however, no study has
been performed to investigate the role of TLR4 in diabetic
retinopathy. In the present study, we evaluated the mRNA and
protein expressions of TLR4 in diabetic retinopathy. Our
results showed that both mRNA and protein levels of TLR4
was significantly elevated after streptozotocin injection, and
increased about 100 % at week 4 in the retina.
The signaling transduction pathways activated by TLRs are
broadly divided into MyD88-dependent and MyD88-
independent pathways [34]. MyD88 is an immediate and
common downstream adaptor molecule recruited by activated
TLRs through their Toll-IL-1 receptor domain. MyD88, in
turn, recruits IRAK and induces phosphorylation. IRAK-1
associates with TRAF 6, leading to the activation of IKK
complex, and resulting in the activation of NF-κB transcrip-
tion factor [35]. The activation of MyD88-dependent signal
transduction pathway causes the production of proinflamma-
tory cytokines, including TNF-α and IL-1β [36]. Following
TLR activation, a MyD88-independent pathway can be
activated when TRIF is recruited in concert with TRAM.
This culminates in MAPK signaling, activation of the tran-
scription factors NF-κB and IRF3, and production of IFN-β
production [37]. The significance of these two different down-
stream pathways and the role of distinct adapter molecules of
TLR4 activation in diabetic retinopathy were also measured in
the present study. Our findings showed that the protein ex-
pressions of MyD88, IRAK, TRAF, TRAM, TRIF, and
NF-κB in DR group were all significantly increased. The
release of inflammatory cytokines (TNF-α and IL-1β) was
associated with a significant increase in NF-κB activity. The
MyD88-independent pathway product IFN-β was also in-
creased in the retina of diabetic rats. These results showed
that TLR4 activated two types of downstream signaling path-
ways, both the MyD88-dependent and MyD88-independent
pathways.
Two TLR4 antagonists, TAK-242 and eritoran tetrasodium
(E5564), have been widely studied. E5564 has a large molec-
ular weight and poor liposolubility, which make it difficult to
cross the blood–brain barrier [38]. On the contrary, TAK-242
has a small molecular weight and high liposolubility [39]. In
the present study, TAK-242 was administered by intraperito-
neal injection. We demonstrated that TAK-242 significantly
reduces MyD88, IRAK, TRAF, TRAM, and TRIF expression
in diabetic retinopathy and inhibits NF-κB activation, thereby
decreasing the release of inflammatory factors TNF-α, IL-1β,
and FN-β, and reduces leukocytes accumulated and retinal
vascular permeability, which ultimately improved diabetic
retinopathy in streptozotocin rats. Therefore, TAK-242 pro-
tects diabetic retinopathy through the mechanism that TAK-
242 downregulates the expression of TLR4 downstream sig-
naling molecules and reduces the NF-κB activation, thereby
alleviating the progression of diabetic retinopathy.
Taken together, our data demonstrate that TLR4 has a
critical role in streptozotocin-induced DR at the level of in-
flammatory cytokine induction, in both the MyD88-dependent
andMyD88-independent pathways. TLR4 inhibition exhibits a
strong protective effect on diabetic retinopathy. These observa-
tions suggest that TLR4-induced pathways may play an impor-
tant role in the pathogenesis of DR, and TLR4 may become a
novel target in the treatment of diabetic retinopathy.
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